Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Cyclerion Therapeutics Inc
CEO
Dr. Peter M. Hecht Ph.D.
Employees
1
Industry
Biotechnology
Sector
Healthcare
Market cap
$4M
Company details
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$1.20
Margin profit
0.00%
52 week low
$1.42
52 week high
$3.94
50-day simple moving average
$1.97
200-day simple moving average
$2.64
Percent held by insiders
21.90%
Percent held by institutions
40.41%
Dividend yield
0.00%
